Jazz Pharmaceuticals and Zymeworks Inc entered into a $50 million licensing agreement over zanidatamab, Zymeworks’ bispecific antibody targeting HER2, the companies announced Wednesday.
The deal will give Jazz exclusive commercialization and development rights over zanidatamab in the U.S., Europe, Japan and all other territories that aren’t yet covered by existing licenses. Aside from the $50 million upfront payment, Jazz is putting $325 million more on the line if it decides to continue the collaboration.
This will be decided once topline data from the HERIZON-BTC-01 trial comes in, which is expected to happen before the year ends.
